Atria Investments Inc Acquires 2,212 Shares of Stryker Co. (NYSE:SYK)

Atria Investments Inc lifted its position in Stryker Co. (NYSE:SYK) by 12.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,395 shares of the medical technology company’s stock after buying an additional 2,212 shares during the period. Atria Investments Inc’s holdings in Stryker were worth $7,299,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Burkett Financial Services LLC bought a new stake in shares of Stryker in the 4th quarter valued at $25,000. Farmers & Merchants Trust Co of Chambersburg PA increased its position in shares of Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after buying an additional 61 shares in the last quarter. Rogco LP bought a new stake in shares of Stryker in the 4th quarter valued at $30,000. Central Pacific Bank Trust Division acquired a new position in Stryker in the 1st quarter worth $39,000. Finally, DSM Capital Partners LLC acquired a new position in Stryker in the 4th quarter worth $34,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Stryker stock traded down $1.61 during trading hours on Friday, hitting $331.56. The company had a trading volume of 1,738,648 shares, compared to its average volume of 1,432,445. Stryker Co. has a one year low of $249.98 and a one year high of $361.41. The firm has a 50-day moving average of $338.87 and a 200 day moving average of $339.61. The firm has a market cap of $126.35 billion, a PE ratio of 37.85, a PEG ratio of 2.57 and a beta of 0.89. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.99.

Stryker (NYSE:SYK) last announced its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The company had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. During the same period last year, the firm earned $2.54 earnings per share. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. On average, sell-side analysts expect that Stryker Co. will post 11.99 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, July 31st. Investors of record on Friday, June 28th were given a dividend of $0.80 per share. The ex-dividend date of this dividend was Friday, June 28th. This represents a $3.20 annualized dividend and a dividend yield of 0.97%. Stryker’s dividend payout ratio is 36.53%.

Analyst Ratings Changes

SYK has been the subject of a number of research analyst reports. Piper Sandler upped their target price on shares of Stryker from $375.00 to $380.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. UBS Group upped their target price on shares of Stryker from $351.00 to $366.00 and gave the stock a “neutral” rating in a research note on Wednesday. Roth Mkm upped their target price on shares of Stryker from $348.00 to $405.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Morgan Stanley increased their price objective on shares of Stryker from $345.00 to $350.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Finally, Barclays increased their price objective on shares of Stryker from $374.00 to $402.00 and gave the stock an “overweight” rating in a research note on Thursday. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $373.11.

Insider Buying and Selling

In related news, CFO Glenn S. Boehnlein sold 20,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the sale, the chief financial officer now owns 2,852 shares in the company, valued at approximately $949,716. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.90% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.